Table 4 shows that, during the 180-day follow-up, MACEs happened in 21 (19.1%) subjects in the high AIM2 level group and 6 (8.2%) subjects in the low AIM2 level group, and the difference was significant (p = 0.042). No significant differences were found between the two groups in cardiogenic death, TVR, heart failure, nonfatal myocardial infarction, and stroke. Kaplan-Meier survival analysis exhibited that CAD patients with high AIM2 levels (>4.9 ng/mL) had a markedly lower survival rate (log-rank p = 0.040) (Figure 3). This evidence concerns the gene AIM2 and Stroke.